Catalent vs Samsung Biologics: CDMO Comparison
Side-by-side comparison of Catalent and Samsung Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Catalent has more FDA inspections on record (10 vs 0) — a deeper regulatory paper trail.
- Catalent has 2 FDA warning letters on record; Samsung Biologics has none.
- Catalent holds 16 active EMA GMP certificates; Samsung Biologics does not appear in EudraGMDP.
- Catalent maintains 16 MHRA / UK GMP certificates; Samsung Biologics does not.
On a 13-modality CDMO landscape, both Catalent and Samsung Biologics qualify as mRNA/LNP manufacturers; Catalent carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both Catalent and Samsung Biologics qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: Catalent vs Samsung Biologics
Which has the stronger FDA inspection record, Catalent or Samsung Biologics?
Catalent has 10 FDA inspections on record (NAI 3 / VAI 6 / OAI 1) and 2 warning letters. Samsung Biologics has 0 FDA inspections on record (NAI 0 / VAI 0 / OAI 0) and 0 warning letters.
How do Catalent and Samsung Biologics compare on European GMP coverage?
Catalent holds 16 active EMA GMP certificates and 16 MHRA / UK certificates. Samsung Biologics holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for mRNA/LNP manufacturing — Catalent or Samsung Biologics?
Both Catalent and Samsung Biologics are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Catalent carries a Signal Score of 76/100 and Samsung Biologics carries 68/100 — a small lead for Catalent. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →